GenEdit Partners with Westwood & Wilshire to Bring on Chief Scientific Officer

South San Francisco, CA, August 30—GenEdit, a Series A gene editing biotech, has brought Romu Corbau on board as its new Chief Scientific Officer. The discovery stage company is exploring multiple therapeutic indications for its technologies in non-viral delivery of CRISPR/ Cas-9 gene editing. This is the second successful placement between Westwood & Wilshire and GenEdit.

This is Dr. Corbau’s second Chief Scientific Officer role, following a four year stint at Freeline in England in which he was promoted twice. With over 22 years in the pharmaceutical and biotech industries, including positions at Pfizer and Spark Therapeutics, Dr. Corbau’s work has covered biologics and gene editing extensively, particularly in discovery and translational phases. Dr. Corbau has over 25 peer-reviewed publications and 11 published or issued patents. He received his PhD in Tumor Virology from the German Center for Cancer Research in Heidelberg, Germany.

The search was successfully led by Tamir Halaban for Westwood & Wilshire’s Life Sciences Practice.

Westwood & Wilshire is a retained executive search firm that recognizes people as any organization’s top asset. The firm has delivered premier talent to many of the world’s most innovative companies in life sciences, healthcare, and advanced technology. Westwood & Wilshire specializes in bringing top-tier candidates at the mid-management to C-Suite level to clients ranging from VC backed start-ups to mid-sized commercial entities. The firm has offices in Los Angeles, Silicon Valley, Scottsdale, and Connecticut serving clients worldwide.